Hyper-coagulation and The Used of Anticoagulant for Patient with COVID-19

Alyssa Claudia V. Gunawan (Alumnus Faculty of Medicine Widya Mandala Catholic University Surabaya)
Bernadette Dian Novita (Department of Pharmacology and Therapy, Faculty of Medicine Widya Mandala Catholic University Surabaya)

Jurnal Widya Medika
Vol. 6 No. 2 (2020): October

Coronavirus SARS-CoV-2 (COVID-19) infection has become a global infection with high mortality and morbidity rate. The pathophysiology of COVID-19 has not yet clear but associated with increasing proinflammatory cytokines and chemokines that leads to cytokine storm. Cytokine storm leads to increasing coagulation that defined by increasing D-dimer, Prothrombin Time (PT), and activated partial thromboplastin time (aPTT). The use of anticoagulant in patient with COVID-19 decrease the mortality rate and become one of the recommended therapy.